Robert N. DeHaven

2.5k total citations
61 papers, 1.9k citations indexed

About

Robert N. DeHaven is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Robert N. DeHaven has authored 61 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 36 papers in Cellular and Molecular Neuroscience and 18 papers in Physiology. Recurrent topics in Robert N. DeHaven's work include Neuropeptides and Animal Physiology (31 papers), Receptor Mechanisms and Signaling (30 papers) and Pharmacological Receptor Mechanisms and Effects (18 papers). Robert N. DeHaven is often cited by papers focused on Neuropeptides and Animal Physiology (31 papers), Receptor Mechanisms and Signaling (30 papers) and Pharmacological Receptor Mechanisms and Effects (18 papers). Robert N. DeHaven collaborates with scholars based in United States and Canada. Robert N. DeHaven's co-authors include Sheng‐Shung Pong, Joel Cassel, Jeffrey D. Daubert, Diane L. DeHaven‐Hudkins, Roland E. Dolle, Erik Mansson, Michael J. Kuhar, Patrick Little, Murray Goodman and Éric Champion and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Robert N. DeHaven

60 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert N. DeHaven United States 24 902 822 625 254 204 61 1.9k
Anna Janecka Poland 26 1.3k 1.4× 1.1k 1.4× 443 0.7× 174 0.7× 246 1.2× 111 2.5k
James L. Ellis United States 31 1.3k 1.5× 653 0.8× 1.1k 1.8× 183 0.7× 252 1.2× 65 3.2k
Canan G. Nebigil France 31 1.7k 1.9× 623 0.8× 408 0.7× 227 0.9× 172 0.8× 67 3.2k
R. Towart Germany 24 1.6k 1.7× 811 1.0× 478 0.8× 139 0.5× 241 1.2× 50 2.7k
Anton D. Michel United Kingdom 28 1.3k 1.5× 917 1.1× 594 1.0× 227 0.9× 261 1.3× 55 2.6k
Ahmad Fawzi United States 22 910 1.0× 493 0.6× 686 1.1× 89 0.4× 243 1.2× 53 2.2k
J Forn United States 28 1.1k 1.3× 778 0.9× 341 0.5× 197 0.8× 645 3.2× 98 2.7k
Tsuyoshi Kihara Japan 18 602 0.7× 332 0.4× 320 0.5× 228 0.9× 144 0.7× 66 1.9k
Deborah Slipetz Canada 22 788 0.9× 439 0.5× 464 0.7× 921 3.6× 187 0.9× 28 2.1k
André De Léan Canada 27 1.5k 1.6× 736 0.9× 360 0.6× 171 0.7× 42 0.2× 64 2.5k

Countries citing papers authored by Robert N. DeHaven

Since Specialization
Citations

This map shows the geographic impact of Robert N. DeHaven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert N. DeHaven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert N. DeHaven more than expected).

Fields of papers citing papers by Robert N. DeHaven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert N. DeHaven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert N. DeHaven. The network helps show where Robert N. DeHaven may publish in the future.

Co-authorship network of co-authors of Robert N. DeHaven

This figure shows the co-authorship network connecting the top 25 collaborators of Robert N. DeHaven. A scholar is included among the top collaborators of Robert N. DeHaven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert N. DeHaven. Robert N. DeHaven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Worm, Karin, Christopher T. Saeui, Joel Cassel, et al.. (2009). Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5004–5008. 6 indexed citations
2.
Chu, Guo‐Hua, Bertrand Le Bourdonnec, Minghua Gu, et al.. (2009). Design and Synthesis of Imidazopyrimidine Derivatives as Potent iNOS Dimerization Inhibitors. PubMed. 3(1). 8–13. 8 indexed citations
3.
Bourdonnec, Bertrand Le, Karin Worm, Catherine Goodman, et al.. (2009). Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability. Bioorganic & Medicinal Chemistry Letters. 20(1). 387–391. 9 indexed citations
4.
DeHaven‐Hudkins, Diane L., Robert N. DeHaven, Patrick Little, & Lee Techner. (2007). The involvement of the μ-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor. Pharmacology & Therapeutics. 117(1). 162–187. 53 indexed citations
5.
Kumar, Virendra, et al.. (2007). Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the κ opioid receptor. Bioorganic & Medicinal Chemistry Letters. 18(12). 3667–3671. 4 indexed citations
6.
Dolle, Roland E., et al.. (2007). Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorganic & Medicinal Chemistry Letters. 17(9). 2656–2660. 5 indexed citations
7.
Bourdonnec, Bertrand Le, Lara K. Leister, Joel Cassel, et al.. (2007). Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 336–343. 9 indexed citations
8.
Kumar, Virendra, Jeffrey D. Daubert, Joel Cassel, et al.. (2005). Amino acid conjugates as κ opioid receptor agonists. Bioorganic & Medicinal Chemistry Letters. 15(5). 1279–1282. 2 indexed citations
9.
DeHaven, Robert N., Erik Mansson, Jeffrey D. Daubert, & Joel Cassel. (2005). Pharmacological Characterization of Human κ / μ Opioid Receptor Chimeras that Retain High Affinity for Dynorphin A. Current Topics in Medicinal Chemistry. 5(3). 303–313. 11 indexed citations
10.
Chu, Guo‐Hua, Minghua Gu, Joel Cassel, et al.. (2005). Novel phenylamino acetamide derivatives as potent and selective κ opioid receptor agonists. Bioorganic & Medicinal Chemistry Letters. 16(3). 645–648. 7 indexed citations
11.
Chu, Guo‐Hua, Minghua Gu, Joel Cassel, et al.. (2005). Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. Bioorganic & Medicinal Chemistry Letters. 15(23). 5114–5119. 21 indexed citations
12.
Bourdonnec, Bertrand Le, Catherine Goodman, Thomas M. Graczyk, et al.. (2005). Synthesis and structure–activity relationships of a new series of 2α-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as μ-selective opioid antagonists. Bioorganic & Medicinal Chemistry Letters. 16(4). 864–868. 2 indexed citations
13.
Bourdonnec, Bertrand Le, Roberta Susnow, Joel Cassel, et al.. (2005). Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorganic & Medicinal Chemistry Letters. 15(10). 2647–2652. 11 indexed citations
14.
Dolle, Roland E., Blanca Martínez‐Teipel, Serge Belanger, et al.. (2004). (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. Bioorganic & Medicinal Chemistry Letters. 14(13). 3545–3548. 21 indexed citations
15.
Tuthill, Paul A., Joel Cassel, Serge Belanger, et al.. (2004). Azepinone as a conformational constraint in the design of κ-opioid receptor agonists. Bioorganic & Medicinal Chemistry Letters. 14(22). 5693–5697. 16 indexed citations
16.
Bourdonnec, Bertrand Le, et al.. (2003). trans -3,4-Dimethyl-4-(3-carboxamidophenyl)piperidines: A novel class of μ-Selective opioid antagonists. Bioorganic & Medicinal Chemistry Letters. 13(24). 4459–4462. 23 indexed citations
17.
Machelska, Halina, et al.. (1999). Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.. PubMed. 290(1). 354–61. 79 indexed citations
18.
19.
Huang, R R, Robert N. DeHaven, A H Cheung, et al.. (1990). Identification of allosteric antagonists of receptor-guanine nucleotide-binding protein interactions.. Molecular Pharmacology. 37(2). 304–310. 62 indexed citations
20.
Jones, Thomas R., Robert Zamboni, Michel Belley, et al.. (1989). Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Canadian Journal of Physiology and Pharmacology. 67(1). 17–28. 232 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Janecka Breakdown of academic impact, for papers by James L. Ellis Breakdown of academic impact, for papers by Canan G. Nebigil Breakdown of academic impact, for papers by R. Towart Breakdown of academic impact, for papers by Anton D. Michel Breakdown of academic impact, for papers by Ahmad Fawzi Breakdown of academic impact, for papers by J Forn Breakdown of academic impact, for papers by Tsuyoshi Kihara Breakdown of academic impact, for papers by Deborah Slipetz Breakdown of academic impact, for papers by André De Léan
Rankless by CCL
2026